2 results for month: 07/2019


PRESENTATION OF THE STUDY SUPPORTED BY RAKFOND AT 2019 ASCO ANNUAL MEETING

Final results of the randomized phase II trial of olanzapine versus aprepitant in patients receiving high-emetogenic chemotherapy were presented by its author Dr. Alexey Rumyantsev at the Annual Meeting of the American Society of Clinical Oncology (ASCO) during the Symptoms and Survivorship session on June 3, 2019, in Chicago, USA...

SUBMISSION OF APPLICATIONS FOR THE CLINICAL RESEARCH PROJECTS COMPETITION IS CLOSED

Ten full applications were received in response to the Request For Proposals for the RakFond's competition of clinical research projects in oncology...